Physician profile
Elson Lai
NPI 1750549192
$49,120.61
in general payments reported to CMS, 2019-2025
34 companies · $4,830 in 2025
The $4,830 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,549 · 2020: $527 · 2021: $1,705 · 2022: $14K · 2023: $15K · 2024: $8,414 · 2025: $4,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $9,974 · Travel and Lodging: $2,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,150.00 |
| Food and Beverage | $9,973.85 |
| Travel and Lodging | $2,509.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $14,226.47 | 2019-2025 | Cequa, Xelpros |
| Sight Sciences, INC. | $12,432.09 | 2021-2025 | Tearcare System, Omni Surgical System |
| Alcon Vision LLC | $8,680.80 | 2019-2025 | Clareon, Unity, Wavelight Refractive Suite |
| Johnson & Johnson Surgical Vision, INC. | $3,442.83 | 2019-2025 | Tecnis Iol, Catalys System |
| Bausch & Lomb Americas INC. | $3,036.21 | 2022-2025 | Envista Mx60 Iol, Amvisc, Stellaris |
| Beaver-Visitec International, INC. | $1,079.54 | 2021-2025 | |
| Allergan, INC. | $976.26 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $817.74 | 2019-2023 | |
| Carl Zeiss Meditec USA, INC. | $731.54 | 2023-2025 | Iolmaster 700, Veracity Surgical, Artevo 800 |
| Tarsus Pharmaceuticals, INC. | $589.78 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $542.91 | 2021-2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Oyster Point Pharma, INC. | $512.52 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $282.14 | 2022-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $252.18 | 2019-2020 | |
| Shire North American Group INC | $192.95 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $166.97 | 2022-2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Lumenis Be INC | $161.16 | 2023 | M22 |
| Ivantis, INC | $133.66 | 2021 | |
| Eyepoint US, INC. | $133.08 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $103.92 | 2021 | |
| Amgen INC. | $95.41 | 2024-2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $86.77 | 2021-2022 | |
| Optos, INC. | $71.75 | 2019-2020 | |
| Abbvie INC. | $63.95 | 2022-2024 | |
| Biotissue Holdings INC. | $52.61 | 2023 | |
| Mallinckrodt Hospital Products INC. | $45.14 | 2022 | |
| Eyevance Pharmaceuticals LLC | $44.53 | 2021-2022 | |
| Horizon Therapeutics Plc | $38.05 | 2023 | Tepezza |
| Harrow Eye, LLC | $32.51 | 2025 | Vevye |
| Lumibird Medical INC. | $21.07 | 2025 | |
| Aerie Pharmaceuticals, INC. | $19.84 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ocular Therapeutix, INC. | $17.59 | 2025 | Dextenza |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elson Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.